ストックスクリーナーアプリを入手
3.72
8.15%
-0.33
アフターアワーズ：
3.75
0.03
+0.81%
前日終値:
$4.05
開ける：
$4.08
24時間の取引高:
67,221
Relative Volume:
0.19
時価総額：
$15.48M
収益：
-
当期純損益:
$-33.44M
株価収益率:
-0.2321
EPS:
-16.0242
ネットキャッシュフロー:
$-28.30M
1週間 パフォーマンス:
-10.79%
1か月 パフォーマンス:
-1.85%
6か月 パフォーマンス:
-87.76%
1年 パフォーマンス:
-98.51%
1日の値動き範囲:
$3.70
$4.095
1週間の範囲:
$3.70
$4.55
52週間の値動き範囲:
$2.78
$330.00
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
3.72 | 16.86M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-10-22 | 開始されました | Truist | Buy |
| 2020-07-24 | 開始されました | Oppenheimer | Outperform |
| 2019-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-10-23 | 開始されました | Citigroup | Buy |
| 2017-10-23 | 開始されました | Jefferies | Buy |
| 2017-10-23 | 開始されました | William Blair | Outperform |
すべてを表示
Nucana Plc Adr (NCNA) 最新ニュース
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma - GlobeNewswire Inc.
NuCana stock rises after securing key patent in China for cancer drug - Investing.com
China grants key patent for NuCana’s cancer drug NUC-7738 - Investing.com
Taking the lead: NuCana plc ADR (NCNA) - Setenews
NuCana compliant with all Nasdaq continued listing criteria - MSN
Rising Momentum in European ADRs: A Strategic Entry Point for US Investors - AInvest
NuCana regains Nasdaq compliance, extends cash runway into 2029 - Investing.com
What recovery options are there for NuCana plc Depositary ReceiptJuly 2025 Update & Expert Curated Trade Ideas - Newser
How institutional ownership impacts NuCana plc Depositary Receipt stockWeekly Trade Recap & Accurate Trade Setup Notifications - Newser
Wall Street Today: Dow, Nasdaq, S&P 500 open flat as investors focus on China tariff deadline; Nvidia down 1.3% - Mint
NuCana plc ADR’s Shares Reel: -92.65% Quarterly Revenue Decline Amid 14.58M Market Cap - investchronicle.com
HEPS’s Stock Dilemma: D-MARKET Electronic Services & Trading ADR’s Market Performance and Outlook - investchronicle.com
NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative
GIBO Holdings Ltd (NASDAQ: GIBO): Down -99.40% In 2025, Outlook Remains Negative - stocksregister.com
What is the dividend policy of NuCana plc Depositary Receipt stockTremendous gains - jammulinksnews.com
NuCana Stock Set to Reverse Split on Friday, August 8th (NASDAQ:NCNA) - Defense World
NuCana Cancels Series A Warrants Post-ATM Execution - The Globe and Mail
NuCana completes cancellation of all remaining Series A Warrants - Investing.com
NCNA’s Market Whiplash: -98.30% YTD Decline, -65.02% Plunge in 30 Days - investchronicle.com
NuCana Announces ADS Ratio Change to Enhance Liquidity - The Globe and Mail
NuCana (NCNA) Announces 1-for-200 Reverse ADS Split Effective Aug 8 2025 - Stock Titan
NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com
Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance. - AInvest
NuCana (NCNA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
NCNA Gets Second Nasdaq Notice; Hearing to Delay Potential Delisting - Stock Titan
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
Market Insight: RxSight Inc (RXST)’s Notable Drop, Closing at 13.50 - DWinneX
nucana plc announces annual report release and upcoming agm - Investing.com India
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNANuCana plc ADR Earnings - Finviz
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
Nucana Plc Share Price (NCNA.US) - London South East
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana (NCNA) Stock Trends and Sentiment 2025 - MarketBeat
NuCana (NCNA) Stock Forecast and Price Target 2025 - MarketBeat
NuCana regains Nasdaq compliance with bid price rule - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
NuCana plcADR (NCNA) Price Target Increased by 15.39% to 5.10 - Nasdaq
NuCana plc (NCNA) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
NuCana plc Sponsored ADR Earnings and Revenue – NASDAQ:NCNA - TradingView
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance
What is the current Price Target and Forecast for NuCana (NCNA) - Zacks Investment Research
Here's What NuCana plc's (NASDAQ:NCNA) Shareholder Ownership Structure Looks Like - Yahoo Finance
Nucana Plc Adr (NCNA) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):